tetano
Editor, Senior Moderator
Am J Physiol Cell Physiol
. 2021 Jan 27.
doi: 10.1152/ajpcell.00478.2020. Online ahead of print.
Soluble ACE2 as a potential therapy for COVID-19
Sudarshan Krishnamurthy[SUP] 1 [/SUP], Richard F Lockey[SUP] 2 [/SUP], Narasaiah Kolliputi[SUP] 2 [/SUP]
Affiliations
Abstract
Soluble angiotensin converting enzyme 2 (sACE2) could be a therapeutic option to treat coronavirus disease 2019 (COVID-19) infection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) utilizes ACE2 receptors on cell surfaces to gain intracellular entry making them an ideal target for therapy. High-affinity variants of sACE2, engineered using high-throughput mutagenesis, are capable of neutralizing COVID-19 infection as decoy receptors. These variants compete with native ACE2 present on cells by binding with spike (S) protein of SARS-CoV2, making native ACE2 on cell surfaces available to convert angiotensin-II to angiotensin-1,7, thus alleviating the exaggerated inflammatory response associated with COVID-19 infection. This article explores the use of sACE2 as potential therapy for COVID-19 infection.
Keywords: ARDS; COVID-19; Lung injury; Soluble ACE2; carona.
. 2021 Jan 27.
doi: 10.1152/ajpcell.00478.2020. Online ahead of print.
Soluble ACE2 as a potential therapy for COVID-19
Sudarshan Krishnamurthy[SUP] 1 [/SUP], Richard F Lockey[SUP] 2 [/SUP], Narasaiah Kolliputi[SUP] 2 [/SUP]
Affiliations
- PMID: 33502950
- DOI: 10.1152/ajpcell.00478.2020
Abstract
Soluble angiotensin converting enzyme 2 (sACE2) could be a therapeutic option to treat coronavirus disease 2019 (COVID-19) infection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) utilizes ACE2 receptors on cell surfaces to gain intracellular entry making them an ideal target for therapy. High-affinity variants of sACE2, engineered using high-throughput mutagenesis, are capable of neutralizing COVID-19 infection as decoy receptors. These variants compete with native ACE2 present on cells by binding with spike (S) protein of SARS-CoV2, making native ACE2 on cell surfaces available to convert angiotensin-II to angiotensin-1,7, thus alleviating the exaggerated inflammatory response associated with COVID-19 infection. This article explores the use of sACE2 as potential therapy for COVID-19 infection.
Keywords: ARDS; COVID-19; Lung injury; Soluble ACE2; carona.